Updated:
Nexus NeuroTech Ventures
Nexus NeuroTech Ventures was a San Francisco venture firm investing across neuroscience and psychiatry — concluded operations March 31, 2026.
Nexus NeuroTech Ventures
Founded in 2023 and based in San Francisco, Nexus NeuroTech Ventures was structured as a private equity firm with a venture capital strategy. The firm focused exclusively on advanced technology-based solutions for neurological and psychiatric disorders. Its mandate spanned the United States, targeting conditions including Parkinson's disease, bipolar disorder, and autism. The firm operated across the full venture lifecycle, from seed and early-stage to expansion and growth equity. It deployed into complex situations as well as general venture rounds — an unusually broad stage remit for a thesis-specific fund. Nexus NeuroTech Ventures did not disclose specific portfolio companies, fund sizes, or co-investor relationships before winding down. Team size, principals, and total deployment were not publicly disclosed. The firm maintained no known additional offices or adjacent philanthropic vehicles. On its own website, Nexus NeuroTech Ventures states it has concluded its operations as of March 31, 2026, with no further detail on the wind-down. The firm's architecture was notable for combining a single-sector neuroscience thesis with venture-stage flexibility, an unusual blend in the digital health landscape. Its relatively short operating window and abrupt conclusion, without publicly named investment leads or portfolio constituents, leave a limited public record of its actual deployment pattern.
General information
Firm type
Venture Capital
Year founded
2023
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
Is Nexus NeuroTech Ventures still an active investor?
No. The firm's website states it concluded its operations as of March 31, 2026. No further details on the wind-down or asset disposition have been made public, and no successor entity has been announced.
What did Nexus NeuroTech Ventures invest in?
The firm targeted advanced technology-based solutions for neurological and psychiatric disorders, including Parkinson's disease, bipolar disorder, and autism. Its investment strategy spanned seed through growth equity. Specific portfolio companies were not publicly disclosed.
What investment stages did Nexus NeuroTech Ventures target?
The firm invested across a wide range of stages: early-stage seed and start-up rounds, expansion and late-stage growth, and complex situations. This broad mandate was unusual for a sector-specific venture platform.
Who founded or ran Nexus NeuroTech Ventures?
Named principals were not publicly disclosed. Neither the firm's website nor other primary sources identified founders, managing partners, or investment committee members before it concluded operations in 2026.
Where did Nexus NeuroTech Ventures deploy capital?
The firm operated across the United States, with a headquarters in San Francisco, California. Its investment focus was domestic, and no international offices or cross-border mandates were disclosed.
How was Nexus NeuroTech Ventures structured?
It was organized as a private equity firm pursuing a venture capital strategy — effectively a single-sector fund targeting neurotech and psychiatric indications. It was not a family office, despite the 'Nexus' naming convention common in that space.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: